🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesType 1.5 diabetes (LADA) and GLP-1 — anyone have experience?

Type 1.5 diabetes (LADA) and GLP-1 — anyone have experience?

marcus_mpls Thu, Mar 5, 2026 at 12:04 PM 12 replies 878 viewsPage 1 of 3
marcus_mpls
Member
234
1,123
Nov 2024
Minneapolis, MN
Mar 5, 2026 at 12:04 PM#1

Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.

What I am trying to establish is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.

Numbers rather than impressions, if you have them.

20 15bbq_ray_KC, oliver_london, tane_welly and 17 others
Reply Quote Save Share Report
sarah.morrison
VIP Member
3,212
14,567
Jan 2024
California
Online
Mar 5, 2026 at 1:16 PM#2
marcus_mpls said:
Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 27 → 15 → 5 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

19 14roxy_nash, tony_orlando, Dr.NephBHM_UK and 16 others
Reply Quote Save Share Report
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
Mar 5, 2026 at 2:28 PM#3
sarah.morrison said:
Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction…

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 37% to 18%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

18 13BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 15 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
traveltech_sara
Member
156
678
Jan 2025
Remote, USA
Mar 5, 2026 at 3:40 PM#4
marcus_mpls said:
Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

This matches mine closely enough to be worth saying so out loud.

17 12NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 14 others
Reply Quote Save Share Report
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Mar 5, 2026 at 10:37 PM#5

From the other side of the consultation, briefly.

PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

After 12 months: periods became regular for the first time in ever, testosterone levels normalized, acne cleared significantly, and — unexpectedly — my hormonal symptoms have almost completely resolved.

GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.

16 11pat_auckland, Dr.GastroMayo, JakeBK_lifts and 13 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register